Pacira Biosciences (PCRX) reported preliminary 2024 revenue Friday of $701 million, up from $675 million a year earlier.
Analysts polled by FactSet expect $695.1 million.
The company also outlined a five-year strategy to expand its focus on musculoskeletal pain and related areas, aiming for growth by 2030.
The plan, called 5x30, includes treating more than 3 million patients annually, achieving double-digit annual revenue growth, increasing gross margins by 5 percentage points, advancing five new clinical programs and establishing five partnerships, Pacira said.
Shares of the company jumped 16% in recent Friday trading.
Price: 21.62, Change: +3.04, Percent Change: +16.36
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.